On February 9th, the Food and Drug Administration (FDA) Arthritis Advisory Committee voted 21-3 in favor of approving the infliximab biosimilar, CT-P13/Inflectra, for use in all of infliximab's indications.
Researchers at Brigham and Women's Hospital, Boston evaluated the efficacy and safety of the anti-inflammatory drug losmapimod on cardiovascular outcomes given to patients with a history of myocardial infarction and CV risk factors.
Systemic sclerosis is one of the most challenging of rheumatic diseases, often complicated by significant morbidity and leads to irreversible disability in many cases.
The American College of Cardiology has released its expert consensus guidance regarding the use of non-statin therapies to lower cholesterol in high-risk patients.
There have been several reports of psoriasis being linked to chronic renal disease in the literature. Another population-based study has also found a link between severe psoriasis and kidney disease.
Knee effusions in osteoarthritis are estimated to occur in 44% of patients, and more than half of these are painful. Management of knee OA with effusions can be problematic given the treatment options and the high recurrence rate.
Opioid use and abuse is at an all time high. Epidemiologic and public health analyses have led to greater stringency and attempts to limit use have adversely effected those with arthritis.
The small molecule oral JAK inhibitor baricitinib was effective for patients with highly refractory rheumatoid arthritis, a phase III study found.
Researchers at the University of Toronto have prospectively studied a cohort of 464 psoriasis patients without a diagnosis of arthritis and followed them over 8 years to estimate the incidence and frequency of psoriatic arthritis (PsA).
(Reuters Health) - Twelve weeks of antibiotic therapy proved ineffective at combating the long-term symptoms seen in some people who have had Lyme disease, a new test of 280 sufferers found. (Citation source http://buff.ly/1Rs21R5)
RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins, wherein we will update you with reports of new, ongoing and resolved Drug Shortages that will affect rheumatology. If you have suggestions or information about specific drug sho
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
